Madrigal Pharmaceuticals just delivered its Q3 2026 scorecard, flipping to a profit while the stock dropped 8.1% to about US$396 in the first trading session after the release. That clash between headlines and price is the story. The company posted US$431.3m in Rezdiffra net sales and logged US$55.4m in net income, the first profitable quarter after a long loss making stretch. Traders marked the share price down. The financials point to a different mood, built around a fast scaling liver disease franchise and a business that is now generating cash instead of burning it.

Love the flip to profitability at Madrigal Pharmaceuticals but concerned about relying on a single fast scaling drug launch for returns? Compare this story against our…